Optimizing HIV testing services in sub-Saharan Africa: cost and performance of verification testing with HIV self-tests and tests for triage.
HIV
ART initiation
HIV self-testing
HIV testing
Quality
Retesting
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
22
05
2018
accepted:
02
01
2019
entrez:
26
3
2019
pubmed:
26
3
2019
medline:
16
7
2020
Statut:
ppublish
Résumé
Strategies employing a single rapid diagnostic test (RDT) such as HIV self-testing (HIVST) or "test for triage" (T4T) are proposed to increase HIV testing programme impact. Current guidelines recommend serial testing with two or three RDTs for HIV diagnosis, followed by retesting with the same algorithm to verify HIV-positive status before anti-retroviral therapy (ART) initiation. We investigated whether clients presenting to HIV testing services (HTS) following a single reactive RDT must undergo the diagnostic algorithm twice to diagnose and verify HIV-positive status, or whether a diagnosis with the setting-specific algorithm is adequate for ART initiation. We calculated (1) expected number of false-positive (FP) misclassifications per 10,000 HIV negative persons tested, (2) positive predictive value (PPV) of the overall HIV testing strategy compared to the WHO recommended PPV ≥99%, and (3) expected cost per FP misclassified person identified by additional verification testing in a typical low-/middle-income setting, compared to the expected lifetime ART cost of $3000. Scenarios considered were as follows: 10% prevalence using two serial RDTs for diagnosis, 1% prevalence using three serial RDTs, and calibration using programmatic data from Malawi in 2017 where the proportion of people testing HIV positive in facilities was 4%. In the 10% HIV prevalence setting with a triage test, the expected number of FP misclassifications was 0.86 per 10,000 tested without verification testing and the PPV was 99.9%. In the 1% prevalence setting, expected FP misclassifications were 0.19 with 99.8% PPV, and in the Malawi 2017 calibrated setting the expected misclassifications were 0.08 with 99.98% PPV. The cost per FP identified by verification testing was $5879, $3770, and $24,259 respectively. Results were sensitive to assumptions about accuracy of self-reported reactive results and whether reactive triage test results influenced biased interpretation of subsequent RDT results by the HTS provider. Diagnosis with the full algorithm following presentation with a reactive triage test is expected to achieve PPV above the 99% threshold. Continuing verification testing prior to ART initiation remains recommended, but HIV testing strategies involving HIVST and T4T may provide opportunities to maintain quality while increasing efficiency as part of broader restructuring of HIV testing service delivery.
Identifiants
pubmed: 30907507
doi: 10.1002/jia2.25237
pmc: PMC6545556
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25237Subventions
Organisme : Bill & Melinda Gates Foundation
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Informations de copyright
© 2019 World Health Organization; licensed by IAS.
Références
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25237
pubmed: 30907507
Lancet HIV. 2018 Jun;5(6):e277-e290
pubmed: 29703707
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21758
pubmed: 28872277
J Int AIDS Soc. 2017 Mar 22;19(1):21345
pubmed: 28364560
PLoS One. 2016 May 09;11(5):e0154893
pubmed: 27159260
PLoS Med. 2013;10(4):e1001414
pubmed: 23565066
J Int AIDS Soc. 2018 Aug;21(8):e25177
pubmed: 30168275
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21755
pubmed: 28872271
J Int AIDS Soc. 2017 Jun 19;20(1):22042
pubmed: 28664683
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Clin Infect Dis. 2017 Aug 1;65(3):522-525
pubmed: 28444206
HIV Clin Trials. 2018 Feb;19(1):15-22
pubmed: 29384717